JMP Securities Downgrades Arbutus Biopharma (ABUS) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Wedbush Downgrades Arbutus Biopharma (ABUS) to Underperform
October 9, 2018 10:10 AM EDTWedbush analyst Robert Driscoll downgraded Arbutus Biopharma (NASDAQ: ABUS) from Neutral to Underperform with a price target of $5.00 (from $7.00).
For an analyst ratings summary and ratings history on Arbutus Biopharma click here. For more ratings news on Arbutus Biopharma click here.
Shares of Arbutus Biopharma closed at $9.09 yesterday.
... More